Fortress Biotech Reports Q2 2024 Financial Highlights
Fortress Biotech reveals Q2 2024 financials with key FDA updates; NDA and BLA filings signal growth in dermatology and oncology.
- Latest
- Trending
Fortress Biotech reveals Q2 2024 financials with key FDA updates; NDA and BLA filings signal growth in dermatology and oncology.
Precision oncology company Boundless Bio is set to go public with a $100 million IPO on the Nasdaq, trading under ...
Sosei Group Corporation announces operational activities and consolidated results, including significant investment, marketing approval, and partnerships. Despite revenue decrease, the ...
NRx Pharmaceuticals receives a $5 million milestone payment for the development of its drug candidate NRX-101, supporting its progress through ...
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
Tonix Pharmaceuticals receives FDA clearance for its OASIS trial, evaluating the efficacy of TNX-102 SL in treating acute stress reactions ...
Investors are turning to psychedelics as a game-changer for mental health. The recent $100 million financing for Lykos Therapeutics shows ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.